Image may be NSFW.
Clik here to view.
Novocure (NSDQ:NVCR) and US Oncology Research said today that the groups are collaborating on a phase III pivotal trial designed to test Novocure’s Tumor Treating Fields with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer.
Using a network of community-based oncology practices, US Oncology Research plans to open 10 clinical trial sites to enroll patients in Novocure’s Panova-3 trial, the companies reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure inks collaboration for pivotal pancreatic cancer trial appeared first on MassDevice.
